Oncoimmunology

雜志介紹

Oncoimmunology雜志介紹

《Oncoimmunology》是一本以English為主的未開放獲取國際優秀期刊，中文名稱腫瘤免疫學，本刊主要出版、報道醫學-IMMUNOLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為6.5，最新CiteScore 指數為12.8。

本刊近期中國學者發表的論文主要有：

• M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance

  Author: Zheng, Naisheng; Wang, Tingting; Luo, Qin; Liu, Yi; Yang, Junyao; Zhou, Yunlan; Xie, Guohua; Ma, Yanhui; Yuan, Xiangliang; Shen, Lisong

• Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome

  Author: Zhang, Peng; Zhao, Yan; Xia, Xin; Mei, Song; Huang, Yixuan; Zhu, Yingying; Yu, Shuting; Chen, Xingming

• Altered phenotypic and metabolic characteristics of FOXP3(+)CD3(+)CD56(+) natural killer T (NKT)-like cells in human malignant pleural effusion

  Author: Wang, Zi-Hao; Zhang, Pei; Peng, Wen-Bei; Ye, Lin-Lin; Xiang, Xuan; Wei, Xiao-Shan; Niu, Yi-Ran; Zhang, Si-Yu; Xue, Qian-Qian; Wang, Hao-Lei; Zhou, Qiong

• Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer

  Author: Wang, Fulong; Lu, Shixun; Cao, Di; Qian, Juanjuan; Li, Cong; Zhang, Rongxin; Wang, Feng; Wu, Miaoqing; Liu, Yifan; Pan, Zhizhong; Wu, Xiaojun; Lu, Zhenhai; Ding, Peirong; Li, Liren; Lin, Junzhong; Catteau, Aurelie; Galon, Jerome; Chen, Gong

英文介紹

Oncoimmunology雜志英文介紹

Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.

OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.